HIMS Quantitative Stock Analysis

Validea's guru fundamental report indicates that HIMS & HERS HEALTH INC (HIMS) receives a 75% rating based on their Small-Cap Growth Investor model, which is based on the Motley Fool strategy. The analysis, which focuses on small-cap growth stocks with strong fundamentals and price performance, highlights strengths in profit margin, relative strength, sales and EPS growth, insider holdings, cash flow from operations, and debt/equity ratio; weaknesses were identified in cash and cash equivalents, the Fool Ratio, average shares outstanding, sales, and daily dollar volume.

Analysis

Hims & Hers Health Inc. (HIMS), identified as a large-cap growth stock in the Biotechnology & Drugs industry, scored 75% according to Validea's Small-Cap Growth Investor model, which emulates the Motley Fool strategy focused on small-cap growth stocks with robust fundamentals and strong price performance. This rating is positioned below the 80% level that typically signals model interest. The analysis reveals several fundamental strengths for HIMS, as it passed criteria for profit margin, relative strength, year-over-year comparison of sales and EPS growth, insider holdings, cash flow from operations, profit margin consistency, R&D as a percentage of sales, inventory to sales, accounts receivable to sales, long-term debt/equity ratio, and current price level. However, the model also highlighted specific weaknesses, with HIMS failing tests related to its cash and cash equivalents, "The Fool Ratio" (P/E to growth), average shares outstanding, absolute sales figures, daily dollar trading volume, and income tax percentage, thereby presenting a mixed fundamental picture through the lens of this particular strategy.

Key Decisions for Investors

• Investors should acknowledge HIMS's positive operational metrics, including strong profit margins, favorable growth comparisons, and healthy debt levels, while noting the 75% score suggests the stock does not fully meet all criteria of this specific small-cap growth model.
• Careful scrutiny should be applied to areas where HIMS failed, specifically its cash and cash equivalents, P/E to growth valuation (Fool Ratio), increases in average shares outstanding, and its absolute sales and daily dollar volume, which may indicate liquidity or scale concerns relative to the model's ideal.
• Consider the context that HIMS, a large-cap stock, is being evaluated by a model designed for small-cap companies, which may influence its performance on certain criteria like sales volume and daily dollar volume.